EVA 001
Alternative Names: EVA-001Latest Information Update: 18 Jan 2022
At a glance
- Originator EVASTEM
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Osteoarthritis
- Research CNS trauma
Most Recent Events
- 21 Dec 2021 Early research in CNS trauma (Recurrent) in Japan (unspecified route) (EVASTEM website, December 2021)
- 27 Jun 2020 Phase-II clinical trials in Osteoarthritis in Japan (Implant) (JapicCTI205401)
- 31 Dec 2012 Korean Pharmaceutical Safety Agency approves EVA 001 in Osteoarthritis of knee and Trauma (EVASTEM website, December 2021)